BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29575509)

  • 1. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of protein induced by vitamin-K absence-II in transplanted patients with HCC not producing alpha-fetoprotein.
    Lai Q; Ito T; Iesari S; Ikegami T; Nicolini D; Larghi Laureiro Z; Rossi M; Vivarelli M; Yoshizumi T; Hatano E; Lerut J
    Liver Transpl; 2024 May; 30(5):472-483. PubMed ID: 37729520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma.
    Masuda T; Beppu T; Horino K; Komori H; Hayashi H; Okabe H; Otao R; Horlad H; Ishiko T; Takamori H; Kikuchi K; Baba H
    J Surg Oncol; 2010 Oct; 102(5):490-6. PubMed ID: 19937994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
    Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
    Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP.
    Baek YH; Lee JH; Jang JS; Lee SW; Han JY; Jeong JS; Choi JC; Kim HY; Han SY
    Hepatogastroenterology; 2009; 56(91-92):763-7. PubMed ID: 19621698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma.
    Hayashi M; Shimizu T; Hirokawa F; Inoue Y; Komeda K; Asakuma M; Miyamoto Y; Takeshita A; Shibayama Y; Tanigawa N
    Am Surg; 2011 May; 77(5):572-8. PubMed ID: 21679590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nomogram to predict microvascular invasion in early hepatocellular carcinoma.
    Li H; Li T; Hu J; Liu J
    J Cancer Res Ther; 2021 Jul; 17(3):652-657. PubMed ID: 34269295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
    Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
    Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
    Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
    Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Tumor Markers After Liver Transplantation In Patients With Hepatocellular Carcinoma.
    Lee TY; Choi HJ; Ahn J; Hong TH; You YK
    Transplant Proc; 2022 Mar; 54(2):461-467. PubMed ID: 35168817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ; Han KH; Kim DY
    Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma.
    Gad A; Tanaka E; Matsumoto A; Wahab MA; Serwah Ael-H; Attia F; Ali K; Hassouba H; el-Deeb Ael-R; Ichijyo T; Umemura T; Muto H; Yoshizawa K; Kiyosawa K
    World J Gastroenterol; 2005 Nov; 11(42):6607-12. PubMed ID: 16425352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCC in living donor liver transplantation: can we expand the Milan criteria?
    Kwon CH; Kim DJ; Han YS; Park JB; Choi GS; Kim SJ; Joh JW; Lee SK
    Dig Dis; 2007; 25(4):313-9. PubMed ID: 17960066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
    Fujioka M; Nakashima Y; Nakashima O; Kojiro M
    Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
    Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
    Mehta N; Dodge JL; Grab JD; Yao FY
    Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.